基于MRI的分期与病理分期预测前列腺癌根治术后生化复发的比较
该回顾性研究纳入604例前列腺癌患者,比较术前MRI与根治术后病理分期特征对生化复发的预测价值。结果显示MRI的包膜外侵犯和精囊侵犯与病理分期预测效能相当,AUC无显著差异,MRI分期可在术前识别高复发风险患者。
要点
- MRI显示包膜外侵犯者3年无生化复发生存率59%,无侵犯者84%。
- MRI显示精囊侵犯者3年无生化复发生存率50%,无侵犯者82%。
- CAPRA-MRI模型与CAPRA-S模型预测生化复发的AUC无显著差异。
核心结论
- 术前MRI分期特征对生化复发的预测效能与术后病理分期特征相当。
- MRI分期可在术前识别高生化复发风险患者,有助于早期临床决策。
研究设计与样本
- 回顾性研究,纳入604例前列腺癌患者(中位年龄60岁),2007年6月至2018年12月行前列腺MRI后接受根治性前列腺切除术。
- 由一名泌尿生殖放射科医生在临床判读中评估MRI的包膜外侵犯和精囊侵犯。
- 采用Kaplan-Meier和Cox比例风险分析评估MRI及病理分期特征对生化复发的预测价值。
- 在374例有活检和病理Gleason分级分组的患者亚组中评估UCSF-CAPRA、CAPRA-S及两个CAPRA-MRI模型。
诊断标准与关键数值
- 生化复发单变量预测因素:MRI包膜外侵犯HR=3.6,MRI精囊侵犯HR=4.4,病理包膜外侵犯HR=5.0,病理精囊侵犯HR=4.6(均p<.001)。
- 无 vs 有包膜外侵犯的3年无生化复发生存率:MRI 84% vs 59%,病理 89% vs 58%(均p<.001)。
- 无 vs 有精囊侵犯的3年无生化复发生存率:MRI 82% vs 50%,病理 83% vs 54%(均p<.001)。
- 病理T3期患者中,MRI无 vs 有T3期的3年无生化复发生存率分别为67%和41%。
- CAPRA模型(含CAPRA-MRI)AUC范围为0.743至0.778,CAPRA-S与CAPRA-MRI模型AUC无显著差异(p>.05)。
临床应用与阅片要点
- 术前MRI评估的包膜外侵犯和精囊侵犯可用于术前识别高生化复发风险患者。
- CAPRA-MRI模型与CAPRA-S模型预测效能相当,可考虑用于术前风险评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Currently most clinical models for predicting biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy (RP) incorporate staging information from RP specimens, creating a gap in preoperative risk assessment. OBJECTIVE. The purpose of our study was to compare the utility of presurgical staging information from MRI and postsurgical staging information from RP pathology in predicting BCR in patients with PCa. METHODS. This retrospective study included 604 patients (median age, 60 years) with PCa who underwent prostate MRI before RP from June 2007 to December 2018. A single genitourinary radiologist assessed MRI examinations for extraprostatic extension (EPE) and seminal vesicle invasion (SVI) during clinical interpretations. The utility of EPE and SVI on MRI and RP pathology for BCR prediction was assessed through Kaplan-Meier and Cox proportional hazards analyses. Established clinical BCR prediction models, including the University of California San Francisco Cancer of the Prostate Risk Assessment (UCSF-CAPRA) model and the Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) model, were evaluated in a subset of 374 patients with available Gleason grade groups from biopsy and RP pathology; two CAPRA-MRI models (CAPRA-S model with modifications to replace RP pathologic staging features with MRI staging features) were also assessed. RESULTS. Univariable predictors of BCR included EPE on MRI (HR = 3.6), SVI on MRI (HR = 4.4), EPE on RP pathology (HR = 5.0), and SVI on RP pathology (HR = 4.6) (all p < .001). Three-year BCR-free survival (RFS) rates for patients without versus with EPE were 84% versus 59% for MRI and 89% versus 58% for RP pathology, and 3-year RFS rates for patients without versus with SVI were 82% versus 50% for MRI and 83% versus 54% for RP histology (all p < .001). For patients with T3 disease on RP pathology, 3-year RFS rates were 67% and 41% for patients without and with T3 disease on MRI. AUCs of CAPRA models, including CAPRA-MRI models, ranged from 0.743 to 0.778. AUCs were not significantly different between CAPRA-S and CAPRA-MRI models (p > .05). RFS rates were significantly different between low- and intermediate-risk groups for only CAPRA-MRI models (80% vs 51% and 74% vs 44%; both p < .001). CONCLUSION. Presurgical MRI-based staging features perform comparably to postsurgical pathologic staging features for predicting BCR. CLINICAL IMPACT. MRI staging can preoperatively identify patients at high BCR risk, helping to inform early clinical decision-making. TRIAL REGISTRATION. ClinicalTrials.gov NCT00026884 and NCT02594202.
引用
- Merriman, Harmon, Belue, et al. Comparison of MRI-Based Staging and Pathologic Staging for Predicting Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. AJR Am J Roentgenol. 2023. PMID: 37404084. doi:10.2214/AJR.23.29609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。